Daehan NupharmLtd (A054670) Stock Overview
Manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
A054670 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Daehan Nupharm Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,170.00 |
| 52 Week High | ₩8,810.00 |
| 52 Week Low | ₩6,300.00 |
| Beta | 0.27 |
| 1 Month Change | 3.91% |
| 3 Month Change | 9.13% |
| 1 Year Change | 2.87% |
| 3 Year Change | -18.62% |
| 5 Year Change | -39.24% |
| Change since IPO | -5.66% |
Recent News & Updates
Recent updates
Solid Earnings May Not Tell The Whole Story For Daehan NupharmLtd (KOSDAQ:054670)
Nov 20
Daehan New Pharm Co., Ltd.'s (KOSDAQ:054670) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 10What Type Of Shareholders Own The Most Number of Daehan New Pharm Co., Ltd. (KOSDAQ:054670) Shares?
Feb 17Here's Why Daehan New Pharm (KOSDAQ:054670) Can Manage Its Debt Responsibly
Jan 21
If You Had Bought Daehan New Pharm's (KOSDAQ:054670) Shares Five Years Ago You Would Be Down 25%
Dec 31Is Daehan New Pharm Co., Ltd.'s(KOSDAQ:054670) Recent Stock Performance Tethered To Its Strong Fundamentals?
Dec 10Shareholder Returns
| A054670 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -3.8% | -0.7% | 6.9% |
| 1Y | 2.9% | 40.5% | 145.2% |
Return vs Industry: A054670 underperformed the KR Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: A054670 underperformed the KR Market which returned 145.2% over the past year.
Price Volatility
| A054670 volatility | |
|---|---|
| A054670 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in KR Market | 16.3% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A054670 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A054670's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Wonseok Lee | www.dhnp.co.kr |
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormones, dermatologic, central nervous system, anticonvulsive, amino acid, anesthetic, antiobesity, and others; vitamins; and inorganic products.
Daehan Nupharm Co.,Ltd. Fundamentals Summary
| A054670 fundamental statistics | |
|---|---|
| Market cap | ₩100.63b |
| Earnings (TTM) | ₩15.26b |
| Revenue (TTM) | ₩202.40b |
Is A054670 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A054670 income statement (TTM) | |
|---|---|
| Revenue | ₩202.40b |
| Cost of Revenue | ₩111.35b |
| Gross Profit | ₩91.05b |
| Other Expenses | ₩75.80b |
| Earnings | ₩15.26b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.09k |
| Gross Margin | 44.99% |
| Net Profit Margin | 7.54% |
| Debt/Equity Ratio | 70.0% |
How did A054670 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/22 01:52 |
| End of Day Share Price | 2026/04/22 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daehan Nupharm Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.